Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RG6344 |
| Synonyms | |
| Therapy Description |
RG6344 is a paradox-breaking BRAF inhibitor, which potentially decreases tumor growth (Cancer Res (2025) 85 (8_Supplement_2): CT017). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RG6344 | RO7276389|RG-6344|RG 6344|RO-7276389|RO 7276389 | BRAF Inhibitor 26 | RG6344 is a paradox-breaking BRAF inhibitor, which potentially decreases tumor growth (Cancer Res (2025) 85 (8_Supplement_2): CT017). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | colorectal cancer | predicted - sensitive | RG6344 | Phase I | Actionable | In a Phase I trial, RG6344 treatment was well tolerated and demonstrated preliminary activity in patients with advanced solid tumors harboring BRAF V600E (n=64), including melanoma (n=11) and colorectal cancer (n=51), with an objective response rate of 25% (Cancer Res (2025) 85 (8_Supplement_2): CT017). | detail... |
| BRAF V600E | melanoma | predicted - sensitive | RG6344 | Case Reports/Case Series | Actionable | In a Phase I trial, RG6344 treatment was well tolerated and demonstrated preliminary activity in patients with advanced solid tumors harboring BRAF V600E (n=64), including melanoma (n=11) and colorectal cancer (n=51), with an objective response rate of 25% (Cancer Res (2025) 85 (8_Supplement_2): CT017). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|